Mercado de biopsia líquida de células tumorales circulantes (CTC) en Oriente Medio y África: tendencias de la industria y pronóstico hasta 2029

Análisis y perspectivas del mercado: mercado de biopsia líquida de células tumorales circulantes (CTC) en Oriente Medio y África

Se espera que el mercado de biopsia líquida de células tumorales circulantes (CTC) de Oriente Medio y África gane crecimiento de mercado en el período de pronóstico de 2022 a 2029. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 16,7% en el período de pronóstico de 2022 a 2029 y se espera que alcance los USD 82,24 millones para 2029 desde USD 24,50 millones en 2021. Es probable que la alta prevalencia de enfermedades crónicas y el aumento de las actividades de I+D para su aplicación efectiva sean los principales impulsores que impulsen la demanda del mercado en el período de pronóstico.

La biopsia líquida es un análisis de sangre no invasivo que detecta las células tumorales circulantes y los fragmentos de ADN tumoral que se liberan en la sangre desde los tumores primarios y las metástasis. Es una alternativa sencilla y precisa a la biopsia quirúrgica, que permite al cirujano detectar el cáncer en una etapa muy temprana.

Las células tumorales circulantes son un subconjunto poco común de células que funcionan como semilla de metástasis. Se encuentran en la sangre de pacientes que han desarrollado tumores sólidos. El análisis de células tumorales circulantes permite la detección y cuantificación de células tumorales en la sangre de pacientes con cáncer. Los diversos tipos de fenotipos biológicos de las células tumorales circulantes (CTC) incluyen células madre o mixtas, mesenquimales o epiteliales. Estos fenotipos están presentes en la sangre en una cantidad muy pequeña. Debido a esto, su detección necesita una fase de aislamiento-enriquecimiento. Después de eso, una segunda fase de detección.

La creciente demanda de biopsia líquida de células tumorales circulantes (CTC) debido a su eficacia y la alta prevalencia del cáncer son los principales impulsores de la demanda del mercado de biopsia líquida de células tumorales circulantes (CTC) en el período de pronóstico. Sin embargo, el escenario regulatorio y de reembolso poco claro y la escasez de personal calificado están restringiendo el crecimiento del mercado de biopsia líquida de células tumorales circulantes (CTC) en el período de pronóstico. 

The Middle East and Africa circulating tumor cells (CTC) liquid biopsy market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope and Market Size

Middle East and Africa circulating tumor cells (CTC) liquid biopsy market is categorized into three notable segments which are based on technology, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of technology, circulating tumor cells (CTC) liquid biopsy market is segmented into CTC detection methods, CTC enrichment methods, ex vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation methods, microchips, single spiral microchannel, negative selection and immunocytochemical technologies  In 2021, CTC detection methods segment is expected to dominate the market because of increasing use of this technology in the academics and research centers for the tests of liquid biopsy.
• On the basis of application, circulating tumor cells (CTC) liquid biopsy market is segmented into cancer stem cell research, multiple chromosome abnormalities and others. In 2021, cancer stem cell research segment is expected to dominate the market because of increasing demand of early diagnosis and treatment of cancer.
• On the basis of end user, circulating tumor cells (CTC) liquid biopsy market is segmented into research and academic institutes, reference laboratories and hospitals and physician laboratories. In 2021, academic and research institutes segment is expected to dominate the market because of research and academic institutes perform an essential role to accelerate research and development in the various therapeutic area related to liquid biopsies.

Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market Country Level Analysis

The Middle East and Africa circulating tumor cells (CTC) liquid biopsy market is analysed and market size information is provided by country, technology, application and end user.

The countries covered in the Middle East and Africa circulating tumor cells (CTC) liquid biopsy market report are South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel and Rest of the Middle East and Africa.

South Africa is expected to dominate the market because of high prevalence of chronic diseases such as cancer and increasing disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data. 

The Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market 

Middle East and Africa circulating tumor cells (CTC) liquid biopsy market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the circulating tumor cells (CTC) liquid biopsy market. The data is available for the historic period 2011 to 2019.

Competitive Landscape and Middle East and Africa Circulating Tumor Cells (CTC) Liquid Biopsy Market Share Analysis

Middle East and Africa circulating tumor cells (CTC) liquid biopsy market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to circulating tumor cells (CTC) liquid biopsy market.

The major companies which are dealing in the circulating tumor cells (CTC) liquid biopsy market are Eurofins Genomics ( a subsidiary of Eurofins Scientific), MDx Health, Guardant Health, IMMUCOR, Thermo Fisher Scientific, Inc., Menarini Silicon Biosystems, QIAGEN, Exact Sciences Corporation, Myriad Genetics, Inc., LungLife AI, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc. , Natera Inc.,  ExoDx ( a subsidiary of Bio-Techne Corporation), Biocept, Inc., F. Hoffman-La Roche Ltd. ,FOUNDATION MEDICINE, INC., Lucence Health, Inc., Inivata Ltd, Biolidics Limited, Vortex Biosciences among others.

For instance,

• En agosto de 2021, Exact Sciences Corporation anunció el rendimiento de la prueba de biopsia líquida hepática Oncogurard, que ofrece una sensibilidad del 82 % en la etapa inicial y una especificidad del 87 %. Esto ayudará a la empresa a avanzar en el trabajo para derrotar al cáncer mediante la detección temprana.

La colaboración, las empresas conjuntas y otras estrategias del actor del mercado están mejorando el mercado de la empresa en el mercado de biopsia líquida de células tumorales circulantes (CTC), lo que también proporciona el beneficio para que la organización mejore su oferta para el mercado de biopsia líquida de células tumorales circulantes (CTC).

SKU-66918